Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by LifeGoesOn1973on Mar 18, 2019 3:45pm
189 Views
Post# 29502318

RE:Fully Diluted Share Increase

RE:Fully Diluted Share Increase
consultant99 wrote:  I was just comparing the March 8th and March 14th share position as posted on the TLT website and noticed that the fully diluted shares of the company had increased from 182,688,640 to 186,657,046 or 3,968,406 shares

Looking closer at the componets the number of outstanding shares has increased by 340,000 shares, the number of outstanding options remain unchanged, and the number of outstanding warrants has increased dramatically by 3,628,406

What did I miss or is this a mistake. I reviewed the INK report and I do not see any changes in insider positions either.

Consultant, the outstanding shares went up from 138.97 in their Feb 1 presentation to 144.13 so that is an increase 5.16 M shares. IMO this is warrant exercise. but I don't understand why they are showing 186.6 M shares fully diluted, it should remain unchanged at 182 M
Bullboard Posts